101
|
Edwards J, Mold F, Knivett D, Boulter P, Firn M, Carey N. Quality improvement of physical health monitoring for people with intellectual disabilities: an integrative review. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH : JIDR 2018; 62:199-216. [PMID: 29193399 DOI: 10.1111/jir.12447] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 10/06/2017] [Accepted: 10/17/2017] [Indexed: 06/07/2023]
|
102
|
Morrow ES, Gujam F, Mohammed ZMA, McMillan DC, Edwards J. Abstract P1-07-06: The relationship between Klintrup-Makinen score and cancer-specific survival in primary operable breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs1-p1-07-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
It is increasingly being recognised that cancer prognosis is dependent on a complex interaction of tumour factors and the host response. The degree of inflammatory response at the invasive tumour edge, as measured by the Klintrup-Makinen score, has been shown to have prognostic relevance in some cancers but its role in breast cancer remains unclear.
Aim
To evaluate the relationship between Klintrup-Makinen score and prognosis in primary operable breast cancer.
Methods
Patients who underwent surgery for primary operable invasive breast cancer between 1995 and 2007 were studied. Full section haematoxylin and eosin slides from surplus tissue from each breast cancer were analysed. Each was visually scored for the level of inflammatory infiltrate at the invasive edge of the tumour, according to Klintrup-Makinen criteria. Kaplan Meier survival analysis was performed using SPSS.
Results
1195 patients were included in the study, of which 298 had a Klintrup-Makinen score (KM) of 0 (no inflammatory cells at the invasive edge), 589 had a score of 1, 238 had a score of 2 and 70 had a Klintrup-Makinen score of 3 (high inflammatory cell infiltrate). 833 (69.7%) patients were ER positive and 172 (14.4%) patients were HER2 positive. Median follow up was 158 months (28-183) and there were 234 cancer deaths. Patients with the highest and lowest KM scores had the best prognosis (10 year breast cancer specific survival (BCSS) 84% for KM score 3 and 82% for KM score 0), while those with KM score 2 had the worst prognosis with 67% 10 year cancer specific survival (p=0.003). When analysed by subtype, in ER negative patients 10 year BCSS was 95% in KM 0 patients, 80% for KM 3, 72% for KM 1 and 67% for KM 2 (p=0.082). Conversely, in HER2 positive patients, the best prognosis was seen in patients with KM 3 with 86% 10 year BCSS but patients with KM 0 had the worst prognosis (BCSS 62%), but this did not reach significance (p=0.544).
Conclusion
The Klintrup-Makinen score appears to have a prognostic role in primary operable invasive breast cancer, however there is a suggestion that it varies between tumour subtypes. Further work is required to further define this role for each molecular subtype.
Citation Format: Morrow ES, Gujam F, Mohammed ZMA, McMillan DC, Edwards J. The relationship between Klintrup-Makinen score and cancer-specific survival in primary operable breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-06.
Collapse
|
103
|
Bayne LJ, Nivar I, Goodspeed B, Wileyto P, Savage J, Shih NNC, Feldman MD, Edwards J, Clark AS, Fox KR, Matro JM, Domchek SM, Bradbury AR, Shah PD, Chislock EM, Belka GK, Wang J, Amaravadi R, Chodosh LA, DeMichele AM. Abstract OT2-07-09: Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-07-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Recurrent breast cancers arise from minimal residual disease (MRD): the pool of disseminated and circulating tumor cells (DTCs and CTCs) that survive in their host following treatment of primary breast cancer. Detection of DTCs in the bone marrow (BM) after treatment is strongly associated with an increased risk of recurrence. Through the analysis of novel genetically-engineered mouse models, we have generated a substantial body of evidence that autophagy and mTOR signaling play key roles in the survival of DTCs. Moreover, administration of agents that block these pathways in mice harboring MRD reduces DTC burden and concomitantly reduces tumor recurrence, providing the rationale for translating these findings to patients (pts).
Trial Design:
The PENN-SURMOUNT screening study uses a clinically validated IHC assay (DTC-IHC) to identify at-risk pts who harbor DTCs. DTC+ pts are eligible for enrollment on the CLEVER trial, which will determine the feasibility, safety and efficacy of administering hydroxychloroquine (HCQ) and/or everolimus (EVE) in DTC+ patients to target MRD and prevent recurrence. PENN-SURMOUNT is single center, prospective cohort study of pts who have completed therapy for primary breast cancer, are within 5 yrs of diagnosis and are at increased risk for relapse by virtue of nodal positivity, triple negative disease, ER+/Oncotype DX RS ≥ 25, or residual disease after neoadjuvant therapy. Pts undergo screening BM aspirate to test for DTCs following completion of adjuvant chemo and radiotherapy. The primary objective of the study is to determine the incidence and frequency of MRD in pts who have completed primary treatment for breast cancer and to ascertain eligibility for the CLEVER recurrence prevention trial.
CLEVER is a randomized, controlled, open label phase II pilot trial. Target enrollment is 60 pts, with 15 pts allocated to each of 4 treatment arms: HCQ (600 mg BID), EVE (10mg daily), combination HCQ/EVE, or control/observation. A cycle is 28 days of continuous dosing. After a 3-month observation period, control pts will be offered HCQ/EVE therapy for 6 cycles; thus, the control group is actually a delayed treatment group and all pts will receive treatment. Pts who demonstrate persistent DTCs after 6 cycles will continue on combination therapy for an additional 6 cycles. The primary endpoint is feasibility of administering HCQ, EVE or the combination in this population. Secondary objectives include safety, efficacy (DTC reduction), and 3-year RFS. The principal translational objective is to assess the utility of a novel DTC assay, "DTC-Flow", for more sensitive detection and response to study therapy, compared to DTC-IHC. Additional translational objectives include determining whether patient DTCs, CTCs, and cell-free circulating plasma tumor DNA (ptDNA) biologically reflect the primary tumor and predict response.
As of 5/23/17, 58 patients have been enrolled to PENN SURMOUNT, with a DTC-positivity rate of 22.6%; CLEVER opened in 2/2017; 11 patients are currently enrolled. Contact information: angela.demichele@uphs.upenn.edu
Key words: Recurrence, disseminated tumor cells, dormancy, minimal residual disease, autophagy, mTOR, Everolimus, hydroxychloroquine
Citation Format: Bayne LJ, Nivar I, Goodspeed B, Wileyto P, Savage J, Shih NNC, Feldman MD, Edwards J, Clark AS, Fox KR, Matro JM, Domchek SM, Bradbury AR, Shah PD, Chislock EM, Belka GK, Wang J, Amaravadi R, Chodosh LA, DeMichele AM. Detection and targeting of minimal residual disease in breast cancer to reduce recurrence: The PENN-SURMOUNT and CLEVER trials [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-07-09.
Collapse
|
104
|
Rawashdeh M, Ganti S, Socci L, Edwards J, Rao J. Trainees Experience in Uniportal VATS Lobectomy for Primary Lung Cancer. A Single UK Centre Study. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
105
|
Edwards J, Chansky K, Shemanski L, Van Schil P, Asamura H, Rami-Porta R. PL 02.06 The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for R Status Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
106
|
Bayman N, Appel W, Ashcroft L, Baldwin D, Bates A, Darlison L, Edwards J, Ezhil V, Gilligan D, Hatton M, Mansy T, Peake M, Pemberton L, Rintoul R, Ryder D, Taylor P, Faivre-Finn C. OA 02.03 Prophylactic Irradiation of Tracts (PIT) in Patients with Pleural Mesothelioma: Results of a Multicenter Phase III Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.330] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
107
|
Praz F, Spargias K, Chrissoheris M, Buellesfeld L, Nickenig G, Deuschl F, Schueler R, Fam N, Moss R, Makar M, Boone R, Edwards J, Moschovitis A, Kar S, Webb J, Schäfer U, Feldman T, Windecker S. TCT-54 First-in-Human Compassionate Use Results of the Novel PASCAL Transcatheter Mitral Valve Repair System for the Treatment of Severe Mitral Regurgitation. J Am Coll Cardiol 2017. [DOI: 10.1016/j.jacc.2017.09.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
108
|
Socci L, Martin-Ucar A, Rawashdeh M, Rao J, Edwards J. P-131SERIES OF AUDITS HELP TO ENSURE THE SUSTAINABILITY OF THE BENEFITS OBTAINED AFTER THE IMPLEMENTATION OF ENHANCED RECOVERY AFTER MAJOR THORACIC SURGERY. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
109
|
Burke A, Telford D, Sutherland B, Sawyez C, Edwards J, Barrett H, Huff M. LDL-CHOLESTEROL, APOB100 KINETICS AND ATHEROSCLEROSIS IN LDLR-DEFICIENT YUCATAN MINIPIGS: A NEW MODEL FOR FAMILIAL HYPERCHOLESTEROLEMIA. Can J Cardiol 2017. [DOI: 10.1016/j.cjca.2017.07.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
110
|
Constâncio V, McAllister M, Patek S, Underwood M, Leung H, Edwards J. Evaluation of combined cytoplasmic AR in tumour cells expression and tumour CD3 T-cells infiltrate as a prognostic score for patients with prostate cancer: PS145. Porto Biomed J 2017; 2:181-182. [PMID: 32258628 DOI: 10.1016/j.pbj.2017.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
111
|
Danson S, Woll P, Edwards J, Blyth K, Fisher P, Roman J, Simpson K, Spavin R, Learmonth K, Conner J. Oncolytic herpesvirus therapy for mesothelioma: A phase I/IIa trial of intrapleural administration of HSV1716 (NCT01721018). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
112
|
Praz F, Spargias K, Chrissoheris M, Büllesfeld L, Nickenig G, Deuschl F, Schueler R, Fam NP, Moss R, Makar M, Boone R, Edwards J, Moschovitis A, Kar S, Webb J, Schäfer U, Feldman T, Windecker S. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet 2017; 390:773-780. [PMID: 28831993 DOI: 10.1016/s0140-6736(17)31600-8] [Citation(s) in RCA: 162] [Impact Index Per Article: 23.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2017] [Revised: 05/09/2017] [Accepted: 05/11/2017] [Indexed: 11/16/2022]
Abstract
BACKGROUND Severe mitral regurgitation is associated with impaired prognosis if left untreated. Using the devices currently available, transcatheter mitral valve repair (TMVr) remains challenging in complex anatomical situations. We report the procedural and 30-day results of the first-in-man study of the Edwards PASCAL TMVr system. METHODS In this multicentre, prospective, observational, first-in-man study, we collected data from seven tertiary care hospitals in five countries that had a compassionate use programme in which patients underwent transcatheter mitral valve repair using the Edwards PASCAL TMVr system. Eligible patients were those with symptomatic, severe functional, degenerative, or mixed mitral regurgitation deemed at high risk or inoperable. Safety and efficacy of the procedure were prospectively assessed at device implantation, discharge, and 30 days after device implantation. The key study endpoints were technical success assessed at the end of the procedure and device success 30 days after implantation using the Mitral Valve Academic Research Consortium definitions. FINDINGS Between Sept 1, 2016, and March 31, 2017, 23 patients (median age 75 years [IQR 61-82]) had treatment for moderate-to-severe (grade 3+) or severe (grade 4+) mitral regurgitation using the Edwards PASCAL TMVr system. At baseline, the median EuroScore II score was 7·1% (IQR 3·6-12·8) and the median Society of Thoracic Surgeons predicted risk of mortality for mitral valve repair was 4·8% (2·1-9·0) and 6·8% (2·9-10·1) for mitral valve replacement. 22 (96%) of 23 patients were New York Heart Association (NYHA) class III or IV at baseline. The implantation of at least one device was successful in all patients, resulting in procedural residual mitral regurgitation of grade 2+ or less in 22 (96%) patients. Six (26%) of 23 patients had two implants. Periprocedural complications occurred in two (9%) of 23 patients (one minor bleeding event and one transient ischaemic attack). Despite the anatomical complexity of mitral regurgitation in the patients in this compassionate use cohort, technical success was achieved in 22 (96%) of 23 patients, and device success at 30 days was achieved in 18 (78%) patients. Three patients (13%) died during the 30 day follow-up. 19 (95%) of 20 patients alive 30 days after implantation were NYHA class I or II. INTERPRETATION This study establishes feasibility of the Edwards PASCAL TMVr system with a high rate of technical success and reduction of mitral regurgitation severity. Further research is needed on procedural and long-term clinical outcomes. FUNDING None.
Collapse
|
113
|
Woodhams R, Evans J, Edwards J, Metcalfe S, Murray P, Arnold J, Wyeth J. Real World Outcomes from Funded Cancer Medicines in New Zealand (NZ) Compared with Published Clinical Trials. Clin Ther 2017. [DOI: 10.1016/j.clinthera.2017.05.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
114
|
Bhatia R, Farkouh M, Ivers N, Yin X, Myers D, Nesbitt G, Yared K, Edwards J, Hansen M, Wong B, Johri A, Udell J, Weinerman A, Rakowski H, Weiner R. P5224Improving the Appropriate Use of Transthoracic Echocardiography- The results of the Echo WISELY trial. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
115
|
Shannon FQ, Horace-Kwemi E, Najjemba R, Owiti P, Edwards J, Shringarpure K, Bhat P, Kateh FN. Effects of the 2014 Ebola outbreak on antenatal care and delivery outcomes in Liberia: a nationwide analysis. Public Health Action 2017; 7:S88-S93. [PMID: 28744445 DOI: 10.5588/pha.16.0099] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2016] [Accepted: 01/31/2017] [Indexed: 11/10/2022] Open
Abstract
Setting: All health facilities, public and private, in Liberia, West Africa. Objectives: To determine access to antenatal care (ANC), deliveries and their outcomes before, during and after the 2014-2015 Ebola outbreak. Design: This was a descriptive cross-sectional study. Result: During the Ebola outbreak in Liberia, overall monthly reporting from health facilities plunged by 43%. Access to ANC declined by 50% and reported deliveries fell by one third during the outbreak. Reported deliveries by skilled attendants and Caesarian section declined by respectively 32% and 60%. Facility-based deliveries dropped by 35% and reported community deliveries fell by 47%. There was an overall decline in reported stillbirths, maternal and neonatal deaths, by 50%, during the outbreak. ANC, reported deliveries and related outcomes returned to pre-outbreak levels within one year following the outbreak. Conclusion: The Liberian health system was considerably weakened during the Ebola outbreak and had difficulties providing basic maternal health services. In the light of the major reporting gaps during the Ebola period, and the reduced use of health facilities for maternal care, these findings highlight the need for measures to avoid such disruptions during future outbreaks.
Collapse
|
116
|
Fam NP, Ho EC, Ahmed N, Edwards J. First transjugular edge-to-edge mitral valve repair with the MitraClip system. EUROINTERVENTION 2017; 13:284-285. [PMID: 28485277 DOI: 10.4244/eij-d-17-00164] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
117
|
Neil-Sztramko SE, Ghayyur A, Edwards J, Campbell KL. Physical Activity Levels of Physiotherapists across Practice Settings: A Cross-Sectional Comparison Using Self-Report Questionnaire and Accelerometer Measures. Physiother Can 2017; 69:152-160. [PMID: 28539695 DOI: 10.3138/ptc.2015-64] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Purpose: This article describes the physical activity of physiotherapists in British Columbia and examines differences across practice settings using self-report questionnaire and accelerometer-derived measures. Methods: Public and private practice physiotherapists aged 18-65 years were recruited through employee email lists and word of mouth to this cross-sectional study. Participants (n=98) completed the International Physical Activity Questionnaire-Long Form (IPAQ-L) online to quantify self-reported physical activity across various domains (occupational, leisure time, domestic, and transportation). Of these, 38 agreed to wear an accelerometer for 7 days to objectively measure physical activity. Descriptive statistics were used to describe self-reported and accelerometer-measured physical activity across domains, and inferential statistics were used to compare physical activity patterns across practice sites. The correlation and agreement between self-report questionnaire and accelerometer measures were also calculated. Results: Almost all (99%) of the physiotherapists self-reported meeting physical activity guidelines, and only 58% were classified as meeting guidelines when using accelerometers. Public practice physiotherapists self-reported more total, occupational, and domestic physical activity and had higher measured occupational physical activity than private practice physiotherapists. Overall, there was poor agreement between self-report questionnaires and accelerometers. Conclusions: Physiotherapists are an active group, with those in public practice reporting and participating in more physical activity than those in private practice.
Collapse
|
118
|
Edwards J, Kane A. Using Data Visualization to Create New Tools for Interactive CHW
Supervision in the Last Mile. Ann Glob Health 2017. [DOI: 10.1016/j.aogh.2017.03.103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
119
|
Alnasser S, Cheema AN, Simonato M, Barbanti M, Edwards J, Kornowski R, Horlick E, Wijeysundera HC, Testa L, Bedogni F, Amrane H, Walther T, Pelletier M, Latib A, Laborde JC, Hildick-Smith D, Kim WK, Tchetche D, Agrifoglio M, Sinning JM, van Boven AJ, Kefer J, Frerker C, van Mieghem NM, Linke A, Worthley S, Asgar A, Sgroi C, Aziz M, Danenberg HD, Labinaz M, Manoharan G, Cheung A, Webb JG, Dvir D. Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis. Circ Cardiovasc Interv 2017; 10:CIRCINTERVENTIONS.116.004392. [DOI: 10.1161/circinterventions.116.004392] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Accepted: 03/21/2017] [Indexed: 11/16/2022]
Abstract
Background—
Transcatheter valve-in-valve implantation is an established therapy for high-risk patients with failed surgical aortic bioprosthesis. There are limited data comparing outcomes of valve-in-valve implantation using different transcatheter heart valves (THV).
Methods and Results—
Patients included in the Valve-in-Valve International Data registry (VIVID) and treated with self-expanding THV devices were analyzed using centralized core laboratory blinded to clinical events. St. Jude Medical Portico versus Medtronic CoreValve were compared in a 1:2 fashion after propensity score matching. A total of 162 patients, Portico- (n=54) and CoreValve- (n=108) based valve-in-valve procedures comprised the study population with no significant difference in baseline characteristics (age, 79±8.2 years; 60% women; mean STS [Society of Thoracic Surgery] score 8.1±5.5%). Postimplantation, CoreValve was associated with a larger effective orifice area (1.67 versus 1.31 cm
2
;
P
=0.001), lower mean gradient (14±7.5 versus 17±7.5 mm Hg;
P
=0.02), and lower core laboratory–adjudicated moderate-to-severe aortic insufficiency (4.2% versus 13.7%;
P
=0.04), compared with Portico. Procedural complications including THV malpositioning, second THV requirement, or coronary obstruction were not significantly different between the 2 groups. Survival and stroke rates at 30 days were similar, but overall mortality at 1 year was higher among patients treated with Portico compared with CoreValve (22.6% versus 9.1%;
P
=0.03).
Conclusions—
In this first matched comparison of THVs for valve-in-valve implantations, Portico and CoreValve demonstrated differences in postprocedural hemodynamics and long-term clinical outcomes. Although this could be related to THV design characteristics, the impact of other procedural factors cannot be excluded and require further evaluation.
Collapse
|
120
|
Marin-Felix Y, Groenewald J, Cai L, Chen Q, Marincowitz S, Barnes I, Bensch K, Braun U, Camporesi E, Damm U, de Beer Z, Dissanayake A, Edwards J, Giraldo A, Hernández-Restrepo M, Hyde K, Jayawardena R, Lombard L, Luangsa-ard J, McTaggart A, Rossman A, Sandoval-Denis M, Shen M, Shivas R, Tan Y, van der Linde E, Wingfield M, Wood A, Zhang J, Zhang Y, Crous P. Genera of phytopathogenic fungi: GOPHY 1. Stud Mycol 2017; 86:99-216. [PMID: 28663602 PMCID: PMC5486355 DOI: 10.1016/j.simyco.2017.04.002] [Citation(s) in RCA: 181] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Genera of Phytopathogenic Fungi (GOPHY) is introduced as a new series of publications in order to provide a stable platform for the taxonomy of phytopathogenic fungi. This first paper focuses on 21 genera of phytopathogenic fungi: Bipolaris, Boeremia, Calonectria, Ceratocystis, Cladosporium, Colletotrichum, Coniella, Curvularia, Monilinia, Neofabraea, Neofusicoccum, Pilidium, Pleiochaeta, Plenodomus, Protostegia, Pseudopyricularia, Puccinia, Saccharata, Thyrostroma, Venturia and Wilsonomyces. For each genus, a morphological description and information about its pathology, distribution, hosts and disease symptoms are provided. In addition, this information is linked to primary and secondary DNA barcodes of the presently accepted species, and relevant literature. Moreover, several novelties are introduced, i.e. new genera, species and combinations, and neo-, lecto- and epitypes designated to provide a stable taxonomy. This first paper includes one new genus, 26 new species, ten new combinations, and four typifications of older names.
Collapse
|
121
|
Rambihar S, Lineberry M, Nesbitt G, Edwards J, Kisselman G, Park YS, Tekian A, Brydges R. ECHO MILESTONES: A NOVEL SIMULATION-BASED ECHOCARDIOGRAPHY COMPETENCE TOOL FOR FORMATIVE ASSESSMENT IN CARDIOLOGY TRAINING. J Am Coll Cardiol 2017. [DOI: 10.1016/s0735-1097(17)35903-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
122
|
Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR. Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Data Brief 2017; 11:364-370. [PMID: 28275670 PMCID: PMC5329066 DOI: 10.1016/j.dib.2017.02.040] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 02/14/2017] [Accepted: 02/15/2017] [Indexed: 01/09/2023] Open
Abstract
The data presented in this article are related to the research article entitled "The autoimmune risk gene ZMIZ1 is a vitamin D responsived marker of a molecular phenotype of multiple sclerosis" Fewings et al. (2017) [1]. Here we identify the set of genes correlated with ZMIZ1 in multiple cohorts, provide phenotypic details on those cohorts, and identify the genes negatively correlated with ZMIZ1 and the cells predominantly expressing those genes. We identify the metabolic pathways in which the molecular phenotype genes are over-represented. Finally, we present the flow cytometry gating strategy we have used to identify the immune cells from blood which are producing ZMIZ1 and RPS6.
Collapse
|
123
|
Fewings NL, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR. The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis. J Autoimmun 2017; 78:57-69. [PMID: 28063629 DOI: 10.1016/j.jaut.2016.12.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Revised: 12/22/2016] [Accepted: 12/24/2016] [Indexed: 01/08/2023]
Abstract
Multiple Sclerosis (MS) is a neurological condition driven in part by immune cells from the peripheral circulation, the targets for current successful therapies. The autoimmune and MS risk gene ZMIZ1 is underexpressed in blood in people with MS. We show that, from three independent sets of transcriptomic data, expression of ZMIZ1 is tightly correlated with that of hundreds of other genes. Further we show expression is partially heritable (heritability 0.26), relatively stable over time, predominantly in plasmacytoid dendritic cells and non-classical monocytes, and that levels of ZMIZ1 protein expression are reduced in MS. ZMIZ1 gene expression is increased in response to calcipotriol (1,25 Vitamin D3) (p < 0.0003) and associated with Epstein Barr Virus (EBV) EBNA-1 antibody titre (p < 0.004). MS therapies fingolimod and dimethyl fumarate altered blood ZMIZ1 gene expression compared to untreated MS. The phenotype indicates susceptibility to MS, and may correspond with clinical response and represent a novel clinical target.
Collapse
|
124
|
McClurg U, Dransfield D, Namdev N, Jacoby D, Chit N, Nakjang S, Edwards J, McCracken S, Robson C. A novel anti-androgen candidate galeterone acts by targeting USP12, a deubiquitinating enzyme that controls prostate cancer growth and survival. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32654-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
125
|
Crous P, Wingfield M, Burgess T, Hardy G, Crane C, Barrett S, Cano-Lira J, Le Roux J, Thangavel R, Guarro J, Stchigel A, Martín M, Alfredo D, Barber P, Barreto R, Baseia I, Cano-Canals J, Cheewangkoon R, Ferreira R, Gené J, Lechat C, Moreno G, Roets F, Shivas R, Sousa J, Tan Y, Wiederhold N, Abell S, Accioly T, Albizu J, Alves J, Antoniolli Z, Aplin N, Araújo J, Arzanlou M, Bezerra J, Bouchara JP, Carlavilla J, Castillo A, Castroagudín V, Ceresini P, Claridge G, Coelho G, Coimbra V, Costa L, da Cunha K, da Silva S, Daniel R, de Beer Z, Dueñas M, Edwards J, Enwistle P, Fiuza P, Fournier J, García D, Gibertoni T, Giraud S, Guevara-Suarez M, Gusmão L, Haituk S, Heykoop M, Hirooka Y, Hofmann T, Houbraken J, Hughes D, Kautmanová I, Koppel O, Koukol O, Larsson E, Latha K, Lee D, Lisboa D, Lisboa W, López-Villalba Á, Maciel J, Manimohan P, Manjón J, Marincowitz S, Marney T, Meijer M, Miller A, Olariaga I, Paiva L, Piepenbring M, Poveda-Molero J, Raj K, Raja H, Rougeron A, Salcedo I, Samadi R, Santos T, Scarlett K, Seifert K, Shuttleworth L, Silva G, Silva M, Siqueira J, Souza-Motta C, Stephenson S, Sutton D, Tamakeaw N, Telleria M, Valenzuela-Lopez N, Viljoen A, Visagie C, Vizzini A, Wartchow F, Wingfield B, Yurchenko E, Zamora J, Groenewald J. Fungal Planet description sheets: 469-557. PERSOONIA 2016; 37:218-403. [PMID: 28232766 PMCID: PMC5315290 DOI: 10.3767/003158516x694499] [Citation(s) in RCA: 151] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Accepted: 11/12/2016] [Indexed: 01/18/2023]
Abstract
Novel species of fungi described in this study include those from various countries as follows: Australia: Apiognomonia lasiopetali on Lasiopetalum sp., Blastacervulus eucalyptorum on Eucalyptus adesmophloia, Bullanockia australis (incl. Bullanockia gen. nov.) on Kingia australis, Caliciopsis eucalypti on Eucalyptus marginata, Celerioriella petrophiles on Petrophile teretifolia, Coleophoma xanthosiae on Xanthosia rotundifolia, Coniothyrium hakeae on Hakea sp., Diatrypella banksiae on Banksia formosa, Disculoides corymbiae on Corymbia calophylla, Elsinoë eelemani on Melaleuca alternifolia, Elsinoë eucalyptigena on Eucalyptus kingsmillii, Elsinoë preissianae on Eucalyptus preissiana, Eucasphaeria rustici on Eucalyptus creta, Hyweljonesia queenslandica (incl. Hyweljonesia gen. nov.) on the cocoon of an unidentified microlepidoptera, Mycodiella eucalypti (incl. Mycodiella gen. nov.) on Eucalyptus diversicolor, Myrtapenidiella sporadicae on Eucalyptus sporadica, Neocrinula xanthorrhoeae (incl. Neocrinula gen. nov.) on Xanthorrhoea sp., Ophiocordyceps nooreniae on dead ant, Phaeosphaeriopsis agavacearum on Agave sp., Phlogicylindrium mokarei on Eucalyptus sp., Phyllosticta acaciigena on Acacia suaveolens, Pleurophoma acaciae on Acacia glaucoptera, Pyrenochaeta hakeae on Hakea sp., Readeriella lehmannii on Eucalyptus lehmannii, Saccharata banksiae on Banksia grandis, Saccharata daviesiae on Daviesia pachyphylla, Saccharata eucalyptorum on Eucalyptus bigalerita, Saccharata hakeae on Hakea baxteri, Saccharata hakeicola on Hakea victoria, Saccharata lambertiae on Lambertia ericifolia, Saccharata petrophiles on Petrophile sp., Saccharata petrophilicola on Petrophile fastigiata, Sphaerellopsis hakeae on Hakea sp., and Teichospora kingiae on Kingia australis.Brazil: Adautomilanezia caesalpiniae (incl. Adautomilanezia gen. nov.) on Caesalpina echinata, Arthrophiala arthrospora (incl. Arthrophiala gen. nov.) on Sagittaria montevidensis, Diaporthe caatingaensis (endophyte from Tacinga inamoena), Geastrum ishikawae on sandy soil, Geastrum pusillipilosum on soil, Gymnopus pygmaeus on dead leaves and sticks, Inonotus hymenonitens on decayed angiosperm trunk, Pyricularia urashimae on Urochloa brizantha, and Synnemellisia aurantia on Passiflora edulis. Chile: Tubulicrinis australis on Lophosoria quadripinnata.France: Cercophora squamulosa from submerged wood, and Scedosporium cereisporum from fluids of a wastewater treatment plant. Hawaii: Beltraniella acaciae, Dactylaria acaciae, Rhexodenticula acaciae, Rubikia evansii and Torula acaciae (all on Acacia koa).India: Lepidoderma echinosporum on dead semi-woody stems, and Rhodocybe rubrobrunnea from soil. Iran: Talaromyces kabodanensis from hypersaline soil. La Réunion: Neocordana musarum from leaves of Musa sp. Malaysia: Anungitea eucalyptigena on Eucalyptus grandis × pellita, Camptomeriphila leucaenae (incl. Camptomeriphila gen. nov.) on Leucaena leucocephala, Castanediella communis on Eucalyptus pellita, Eucalyptostroma eucalypti (incl. Eucalyptostroma gen. nov.) on Eucalyptus pellita, Melanconiella syzygii on Syzygium sp., Mycophilomyces periconiae (incl. Mycophilomyces gen. nov.) as hyperparasite on Periconia on leaves of Albizia falcataria, Synnemadiella eucalypti (incl. Synnemadiella gen. nov.) on Eucalyptus pellita, and Teichospora nephelii on Nephelium lappaceum.Mexico: Aspergillus bicephalus from soil. New Zealand: Aplosporella sophorae on Sophora microphylla, Libertasomyces platani on Platanus sp., Neothyronectria sophorae (incl. Neothyronectria gen. nov.) on Sophora microphylla, Parastagonospora phoenicicola on Phoenix canariensis, Phaeoacremonium pseudopanacis on Pseudopanax crassifolius, Phlyctema phoenicis on Phoenix canariensis, and Pseudoascochyta novae-zelandiae on Cordyline australis.Panama: Chalara panamensis from needle litter of Pinus cf. caribaea. South Africa: Exophiala eucalypti on leaves of Eucalyptus sp., Fantasmomyces hyalinus (incl. Fantasmomyces gen. nov.) on Acacia exuvialis, Paracladophialophora carceris (incl. Paracladophialophora gen. nov.) on Aloe sp., and Umthunziomyces hagahagensis (incl. Umthunziomyces gen. nov.) on Mimusops caffra.Spain: Clavaria griseobrunnea on bare ground in Pteridium aquilinum field, Cyathus ibericus on small fallen branches of Pinus halepensis, Gyroporus pseudolacteus in humus of Pinus pinaster, and Pseudoascochyta pratensis (incl. Pseudoascochyta gen. nov.) from soil. Thailand: Neoascochyta adenii on Adenium obesum, and Ochroconis capsici on Capsicum annuum. UK: Fusicolla melogrammae from dead stromata of Melogramma campylosporum on bark of Carpinus betulus. Uruguay: Myrmecridium pulvericola from house dust. USA: Neoscolecobasidium agapanthi (incl. Neoscolecobasidium gen. nov.) on Agapanthus sp., Polyscytalum purgamentum on leaf litter, Pseudopithomyces diversisporus from human toenail, Saksenaea trapezispora from knee wound of a soldier, and Sirococcus quercus from Quercus sp. Morphological and culture characteristics along with DNA barcodes are provided.
Collapse
|